Term of the Research Program. The term of the Research Program shall initially be for a period of [***] after the Effective Date (the “Research Program Term”), unless terminated earlier in accordance with Article 13.
Term of the Research Program. The term of the Research Program shall commence on the Effective Date and, unless terminated earlier pursuant to Section 2.4.2 or Article 19 or extended by mutual agreement of the Parties, shall terminate on the fifth anniversary of the Effective Date; provided, if an IND has been filed in the Territory with respect to a Collaboration Product for treatment of each of CAD and PVD prior to the fifth anniversary of the Effective Date, the Research Program may be terminated earlier with the written agreement of the Parties (the "Term of the Research Program").
Term of the Research Program. The term of the Research Program shall be for a period commencing the Effective Date and end on the date of delivery of the Final Phase I/II Report, but in no event later than [*] (the “Research Program Term”), unless terminated earlier upon termination of this Agreement in accordance with Article 14 hereof.
Term of the Research Program. The Research Program shall expire five (5) years after the Effective Date unless extended as provided below or unless earlier terminated by either Party by virtue of termination of the Research Program or this Agreement pursuant to the provisions of Sections 2.3.3 or 2.3.4 and/or Article 8 (the "Research Term").
Term of the Research Program. Unless this Agreement is earlier terminated, the term of the Research Program shall commence on the Effective Date and shall continue through completion of all Work Plans for Research Antigens for which CuraGen has delivered to ABX for immunization on or prior to June 30, 2005 an immunogen meeting the Work Plan criteria for such Research Antigen (the “Last Immunization Date”). Without limiting the generality of the foregoing, CuraGen will have no obligation to deliver Research Antigens after June 30, 2005 and ABX will have no obligation to immunize Xenomouse Animals with Research Antigens delivered after June 30, 2005 or conduct any further work with respect to such unimmunized antigens. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential Investment under Rule 24b-2 under the Securities Exchange Act of 1934.
Term of the Research Program. 7.6.1. The term of the Research Program shall be two (2) years as from the fifteenth day after the Operational Date, unless terminated earlier upon termination of this Agreement in accordance with Article 14 hereof.
Term of the Research Program. The initial term of the Research Program shall be for a period of three (3) years from the Effective Date (the "INITIAL RESEARCH PROGRAM TERM"), unless terminated earlier upon termination of this Agreement in accordance with Article 15 hereof. Subject to the written approval of SGI and to payment of the fee by EOS to extend, as set forth in Section 3.4(d) below, the Research Program will be extended for [***] additional period of [***] upon EOS's request by giving written notice to SGI not less than [***] prior to the expiration of the Initial Research Program Term (collectively with the Initial Research Program Term, the "RESEARCH PROGRAM TERM").
Term of the Research Program. The term of the Research Program for Designated Target Antigen [***] commenced upon approval of the corresponding Research Plan under Section 2.4.3 of this Agreement as revised pursuant to the Second Amendment and in effect upon the Second Amendment Effective Date, and the term of each subsequent Research Program shall commence upon approval of a Research Plan under Section 2.4.3 of this Agreement; provided, that the term of the Research Program with respect to any Replacement Antigen shall commence upon approval of the Research Plan under Section 2.4.5. The term of each Research Program shall continue until the earlier of (a) the later of (i) completion of MTI’s activities set forth in the Research Plan, including the disclosure and delivery by MTI to Licensee of any and all results, information, materials and other deliverables contemplated thereunder and (ii) [***] months following commencement of the Research Plan plus any extensions as set forth below in this Section 2.3 and (b) if such Target is Designated Target Antigen [***] (each such period, a “Research Program Term”). If Licensee requires additional time to conduct its evaluation and research activities under a Research Plan or if any amendment [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Term of the Research Program. The term of the Research Program (the “Research Term”) shall commence upon the earlier of (i) [***] days after the Effective Date or (ii) the date of approval of the initial Research Plan by the JRC (“Research Commencement Date”), and shall continue thereafter for an initial period of three (3) years. The Research Term shall expire on the third anniversary of the Research Commencement Date, unless extended by mutual written agreement of the Parties or earlier terminated in accordance with this Agreement.
Term of the Research Program. The term of the Research Program shall initially be for a period of [***] after the Effective Date (the “Research Program Term”), unless terminated earlier in accordance with Article 13. Licensee shall have the one-time right to extend the Research Program Term for an additional [***] by providing written notice to Licensor and paying a fee of [***] to the expiration of the initial Research Program Term.
